1,064 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. purchased a new position in Insulet Co. (NASDAQ:PODD) in the fourth quarter, Holdings Channel reports. The fund purchased 1,064 shares of the medical instruments supplier’s stock, valued at approximately $278,000.

Other institutional investors also recently added to or reduced their stakes in the company. Inceptionr LLC purchased a new stake in shares of Insulet during the 4th quarter worth approximately $1,327,000. Raymond James Financial Inc. purchased a new stake in shares of Insulet during the 4th quarter worth approximately $69,433,000. Arizona State Retirement System lifted its position in shares of Insulet by 1.4% during the 4th quarter. Arizona State Retirement System now owns 20,343 shares of the medical instruments supplier’s stock worth $5,311,000 after buying an additional 276 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Insulet during the 4th quarter worth approximately $28,422,000. Finally, Atria Investments Inc lifted its position in shares of Insulet by 9.1% during the 4th quarter. Atria Investments Inc now owns 6,035 shares of the medical instruments supplier’s stock worth $1,576,000 after buying an additional 502 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PODD shares. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Raymond James restated an “outperform” rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, Royal Bank of Canada started coverage on shares of Insulet in a report on Thursday. They issued an “outperform” rating and a $340.00 target price on the stock. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

Shares of PODD opened at $251.81 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $17.68 billion, a P/E ratio of 43.49, a P/E/G ratio of 3.62 and a beta of 1.29. The company’s fifty day moving average is $274.09 and its two-hundred day moving average is $253.33. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, sell-side analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.